Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617821 | 1.00 | PDK1 (0.45) | PDK1KMT2AMEN1MMP13EPHA2 | |
| SCHEMBL617822 | 1.00 | PDK1 (0.45) | PDK1KMT2AMEN1MMP13EPHA2 | |
| SCHEMBL31494035 | 0.91 | EPHA2 (0.42) | PDK1KMT2AMEN1MMP13EPHA2 | |
| SCHEMBL7291444 | 0.91 | STS (0.49) | KMT2AMEN1EPHA2GPR119ERBB2 | |
| SCHEMBL12527484 | 0.90 | KMT2A (0.43) | PDK1KMT2AMEN1MMP13EPHA2 | |
| SCHEMBL9216185 | 0.88 | ALDH1A1 (0.49) | MMP13EPHA2GPR119ERBB2EPHB4 | |
| SCHEMBL9214380 | 0.88 | ALDH1A1 (0.49) | MMP13EPHA2GPR119ERBB2EPHB4 | |
| SCHEMBL9215446 | 0.88 | ALDH1A1 (0.49) | MMP13EPHA2GPR119ERBB2EPHB4 | |
| SCHEMBL618279 | 0.85 | PDK1 (0.49) | PDK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL4402755 | 0.85 | PDK1 (0.49) | PDK1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085066-A1 | LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-20100210640-A1 | BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2010-08-19 | — | — | US | disclosed |
| EP-2197874-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| EP-2189451-A1 | BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-05-26 | — | — | EP | disclosed |
| EP-2189451-A1 | BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008157330-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0411912-B1 | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | SANKYO CO (JP) | 1995-04-19 | — | — | EP | disclosed |
| EP-0411912-A2 | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | Sankyo Company Limited (JP) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | PDK1 1366/4885KMT2A 1251/4885MEN1 2327/4885 |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | PDK1 1366/4885KMT2A 1251/4885MEN1 2327/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | PDK1 1366/4885KMT2A 1251/4885MEN1 2327/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | PDK1 2125/4885KMT2A 865/4885MEN1 1946/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | PDK1 2611/4885KMT2A 3560/4885MEN1 3634/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | PDK1 907/4885KMT2A 4097/4885MEN1 4081/4885 |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | PDK1 647/4885KMT2A 2659/4885MEN1 3588/4885 |
| US-20100210640-A1 | BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF | HTR4, HTR5A, TPH1 | PDK1 1558/4885KMT2A 3292/4885MEN1 1659/4885 |
| US-20260085066-A1 | LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, PARK7, NEDD4 | PDK1 1325/4885KMT2A 825/4885MEN1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.